Methods of treatment

Patent metadata

Field	Value
Publication number	US-10004725-B2
Application number	US-201615084252-A
Country	US
Kind code	B2
Filing date	Mar 29, 2016
Priority date	Mar 30, 2015
Publication date	Jun 26, 2018
Grant date	Jun 26, 2018

Abstract

This disclosure relates to use of certain aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal.

First claim

What is claimed is:

1. A method of treating idiopathic pulmonary fibrosis in a patient, the method comprising administering to said patient a therapeutically effective amount of a compound selected from:
(S)-2-hydroxy-6-((1-(6-methoxynicotinoyl)piperidin-2-yl)methoxy)benzaldehyde; and
2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; or
a pharmaceutically acceptable salt thereof.

2. A method of treating idiopathic pulmonary fibrosis in a patient, the method comprising administering to said patient a therapeutically effective amount of a compound, wherein the compound is 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde.

3. The method of claim 2 , wherein the patient is administered 500 to 1000 mg of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde per day.

4. The method of claim 2 , wherein the patient is administered 600 to 900 mg of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde per day as a single dose.

5. The method of claim 2 , wherein the compound is an ansolvate characterized by at least two X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ).

6. The method of claim 5 , wherein the compound is characterized by at least three X-ray powder diffraction peak (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ).

Assignees

• Global Blood Therapeutics Inc

Inventors

• Dufu Kobina N
• Geng Xin
• Sinha Uma

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61P19/04

  for non-specific disorders of the connective tissue · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title